Skip to main content
KyungdongPharm logo

KyungdongPharm — Investor Relations & Filings

Ticker · 011040 ISIN · KR7011040003 KO Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2023-10-17 Director's Dealing
Country KR South Korea
Listing KO 011040

About KyungdongPharm

https://kdpharma.co.kr

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This document details the shareholding changes of a specific individual (Ryu Deok-hee, Honorary Chairman) in Kyungdong Pharmaceutical Co., Ltd. Such filings, which report personal share transactions by company directors and executives, are classified as 'Director's Dealing' (DIRS).
2023-10-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document discloses changes in share ownership by major shareholders and their special relations, including details on collateral contracts and shareholding percentages. This falls under the 'Major Shareholding Notification' category.
2023-08-29 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares by the Largest Shareholder' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). This type of disclosure is a standard regulatory requirement for listed companies to report changes in collateralized shares held by major shareholders. Since it does not fit into specific categories like 'Director's Dealing' (which usually refers to personal trades) or 'Share Issue', it falls under the general regulatory filing category.
2023-08-25 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Kyung Dong Pharmaceutical Co., Ltd. for the period of January 1, 2023, to June 30, 2023. It contains detailed financial statements, business operations, management discussion, and governance information, which are characteristic of an interim/quarterly report. It is not an announcement of a report (RPA) as it contains the full content of the report itself. H1 2023
2023-08-14 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Kyung Dong Pharmaceutical Co., Ltd. covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding status of a specific individual (Nam Ki-cheol) who is an executive at Kyungdong Pharmaceutical. This type of filing is a standard regulatory requirement for directors and executives to disclose their personal share transactions or holdings, which falls under the 'Director's Dealing' category.
2023-04-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.